Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Washington Marriott Wardman Park

Oct 29, 2014 8:00 AM - Oct 30, 2014 4:00 PM

2660 Woodley Road, NW, , Washington, DC 20008 , USA

Patient Engagement throughout the Full Spectrum of Drug Development: An Interactive Workshop for Life Science Companies and Patient Groups

Session 1: Profile - The Many Faces of Patients and Patient Engagement

Session Chair(s)

Carl  Chiang

Carl Chiang

Director, Clinical Development

Zinfandel Pharmaceuticals, United States

There is a growing awareness that the input of the patient is critical to the development of treatments that, beyond being effective and safe, address important medical needs and improve the quality of patient lives. We hear about patient engagement, patient advocacy and patient-centric practice – – are they the same and what do these endeavors mean to patients, to researchers, to regulators? And who is the patient? Through facilitated discussion with an expert panel, workshop participants will examine these important questions that are key to implementing effective patient engagement efforts.

Speaker(s)

James  Valentine, JD, MHS

Moderator

James Valentine, JD, MHS

Hyman, Phelps & McNamara, PC, United States

Director

Lode  Dewulf

Lode Dewulf

Corvalus, Belgium

Patient and Medical Affairs Consultant

Mary  Dwight

Mary Dwight

Cystic Fibrosis Foundation, United States

Vice President for Government Affairs

Megan L. O'Boyle

Megan L. O'Boyle

Phelan-Mcdermid Syndrome Foundation, United States

PI, PMSIR (patient registry), PMS_DN (PCORI data sharing project)

Suzanne  Schrandt, JD

Suzanne Schrandt, JD

ExPPect, United States

Founder, Chief Executive Office and Chief Patient Advocate

Thomas P. Sellers, MPA

Thomas P. Sellers, MPA

Millennium: The Takeda Oncology Company, United States

Senior Director, Patient Advocacy & Corporate Philanthropy

Open Floor  Discussion

Discussion 1: Engagement, Advocacy, Patient-centric Practice - Are They the Same? What do These Endeavors Mean to Patients, to Researchers, to Regulators?

Open Floor Discussion

United States

Open Floor  Discussion

Discussion 2: Who is the Patient? Patients and Patient Groups; Patients and Caregivers; Patients with Rare Diseases, with Chronic Disease, and with Serious Acute Disease

Open Floor Discussion

United States

Open Floor  Discussion

Discussion 3: Patient Populations - Navigating Stages of Maturation

Open Floor Discussion

United States

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.